+7 (777) 001 44 99
Қазақша
Русский
English
02 December 2024 | 16:54
Testing of Kazakhstani cancer drug: what is known
Tengrinews.kz - Kazakh scientists continue to conduct clinical trials of the developed anti-cancer drug, according to the Government press service.
ПОДЕЛИТЬСЯ
Tengrinews.kz - Kazakh scientists continue to conduct clinical trials of the developed anti-cancer drug, according to the Government press service.
As reported by biologist, professor Dos Sarbassov, the anti-cancer drug has successfully passed two initial phases.
"After the first dose of the drug, the condition of 15 cancer patients stabilized, the tumor stopped growing in six of them, and even shrank in one. At the moment, the patients' dose of the drug has been increased, taking into account that doctors have confirmed the absence of toxicity," Dos Sarbassov said.
As he specified, testing of the anti-cancer drug began in 2022-2023 after receiving permits.
"We hit cancer cells that absorb glucose. Our patent is international. The effect showed stabilization in the control group. The tumor did not grow, and in one patient it shrank by 30 percent. We need to see this through to the end - we must complete the project within 2-3 years," Dos Sarbassov added.
Tests of the anti-cancer drug are being conducted at the Kazakh Institute of Oncology and Radiology.
Earlier, the biologist reported that already at the first stage of clinical trials, the patients' condition stabilized, and one of them had a tumor shrinkage. Initially, the drug was administered to patients in small doses to determine the optimal, maximum tolerated dose for treatment effectiveness. It was also noted that it was necessary to understand which type of cancer would be most sensitive to this drug.
He explained that the drug's action is based on targeted chemotherapy. The drug causes mutated cancer cells (KRAS mutant cells) to self-destruct due to a combination of a high dose of D-form of vitamin C (D-VC) with arsenic in a low concentration.
According to him, a limited batch of D-form of vitamin C (DV-C) was released at a pharmacological plant in Almaty. Arsenic oxide, in turn, was purchased in India.
The drug is administered intravenously. The patient receives 18 injections: one 6 times a week. In this case, arsenic oxide and vitamin are administered separately, with an interval of two hours. After three weeks, there is a week-long break, after which the person receives the next 18 injections.
When asked when the Kazakh cancer drug will be fully ready, Sarbasov stated that it will not be earlier than "in 2-3 years."
Показать комментарии
Читайте также
